Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL®…
Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates November 10, 2026 at 7:00 AM EST Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026
How this was made
The 30-second read
Why it matters
The earnings beat and raised revenue guidance provide fresh, material information for traders.
Market read
First‑report earnings and guidance raise for a biotech with active clinical programs; likely to move the stock and influence sector sentiment.
What to watch
Potential execution risk on upcoming trial readouts and regulatory milestones could temper upside.
AUCATZYL net product revenue rose 95% year-over-year to $41.2 million; company now expects full-year 2026 AUCATZYL net product revenue at or exceeding the upper end of $150 million
Product revenue growth (95% year-over-year) and a reported gross margin of 57% are strong, and the full-year revenue outlook was raised. Operating and net losses remain large, shareholders' equity fell to $27,396 thousand, and total liabilities exceed $495 million, so the balance sheet and funding runway carry significant weight.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, net (three months ended Sep 30, 2026)GAAP | $41.2M | – | 95% |
| Total revenue, net (three months ended Sep 30, 2026)GAAP | $41.24M | – | – |
| Product revenue, net (nine months ended Sep 30, 2026)GAAP | $113.1M | – | – |
| Total revenue, net (nine months ended Sep 30, 2026)GAAP | $113.1M | – | – |
| Cost of sales (three months ended Sep 30, 2026)GAAP | $17.9M | – | – |
| Cost of sales (nine months ended Sep 30, 2026)GAAP | −$62.96M | – | – |
| Gross margin (three months ended Sep 30, 2026)other | 57% | – | – |
| Research and development expenses, net (three months ended Sep 30, 2026)GAAP | $30.9M | – | – |
| Research and development expenses, net (nine months ended Sep 30, 2026)GAAP | −$80.01M | – | – |
| Selling, general and administrative expenses (three months ended Sep 30, 2026)GAAP | $35.9M | – | – |
| Selling, general and administrative expenses (nine months ended Sep 30, 2026)GAAP | −$117.1M | – | – |
| Loss from operations (three months ended Sep 30, 2026)GAAP | $43.5M | – | – |
| Loss from operations (nine months ended Sep 30, 2026)GAAP | −$146.9M | – | – |
| Total other (expenses) income, net (three months ended Sep 30, 2026)GAAP | −$12.04M | – | – |
| Total other (expenses) income, net (nine months ended Sep 30, 2026)GAAP | −$18.07M | – | – |
| Income tax benefit (expense) (three months ended Sep 30, 2026)GAAP | $489K | – | – |
| Net loss (three months ended Sep 30, 2026)GAAP | $55.1M | – | – |
| Net loss (nine months ended Sep 30, 2026)GAAP | −$165.8M | – | – |
| Basic and diluted net loss per ordinary share (three months ended Sep 30, 2026)GAAP | $(0.21) | – | – |
| Basic and diluted net loss per ordinary share (nine months ended Sep 30, 2026)GAAP | $(0.62) | – | – |
| Total comprehensive loss (three months ended Sep 30, 2026)GAAP | −$54.61M | – | – |
| Cash, cash equivalents and marketable securities (at Sep 30, 2026)other | $248.4M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| AUCATZYL net product revenuePer the company, net revenues were primarily driven by increasing product demand both within existing treatment centers and expansion into new centers, supplemented by contribution from UK sales. | $41.2 million (three months ended Sep 30, 2026) | – | 95% |
| License revenueNo driver is given in the filing for this line. | — (three months ended Sep 30, 2026; $50 thousand in the same period of 2025) | – | – |
FY2026 outlook
- RevenueAUCATZYL net product revenue at or exceeding the upper end of $150 million
- NoteCash, cash equivalents and marketable securities expected to be sufficient to fund operations into Q2 2028, based on current operating plans, anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling $100 million from the Perceptive credit facility (company statement).
Capital returns
- No share repurchases or dividends are reported in the filing.
What drove it
- Company explanation: AUCATZYL revenue growth was primarily driven by growth within existing authorized treatment centers as physicians gain experience with the therapy, and supported by real-world data reported through the ROCCA consortium.
- Company explanation: gross margin improvement over the prior year was primarily driven by a reduction in manufacturing cost per batch, reflecting increased volumes and ongoing operational efficiency initiatives, and by lower inventory reserves and write-offs compared with the same period in 2025.
- Company explanation: the R&D increase was primarily due to higher clinical manufacturing supply costs driven by clinical development activities, partially offset by lower salaries and other employment-related costs.
- Company explanation: the SG&A decrease was primarily due to lower salaries, other employment-related costs and professional fees supporting commercialization activities in the US and UK.
- Company explanation: the cash balance increase in the quarter was primarily driven by net cash inflows from the Perceptive Advisors senior secured note facility.
- The company raised its full-year 2026 AUCATZYL net product revenue expectation to at or exceeding the upper end of $150 million.
Concerns
- Loss from operations was $43.5 million and net loss was $55.1 million for the quarter; nine-month net loss was $(165,800) thousand.
- Total shareholders' equity fell to $27,396 thousand at Sep 30, 2026 from $178,129 thousand at Dec 31, 2025, while total liabilities rose to $495,663 thousand from $410,939 thousand.
- The company's funding runway into Q2 2028 depends on AUCATZYL revenues and the $100 million combined first and second tranches from the Perceptive credit facility, as stated in the filing.
- Other (expense) income, net was $(12,045) thousand in the quarter against $(6,965) thousand a year earlier; the filing does not explain this line.
- The filing's safety information reports, for the FELIX study, 9 patients (9%) with fatal adverse reactions, and a warning covering cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies.
- The company moved the first progressive MS data presentation to ECTRIMS Global in October 2027, following KOL feedback that longer follow-up is required.
What to watch
- Delivery against the full-year 2026 AUCATZYL net product revenue expectation of at or exceeding the upper end of $150 million.
- Gross margin trajectory from 55% in Q2 2026 to 57% in Q3 2026, and whether manufacturing efficiency gains continue.
- Timing of Perceptive credit facility tranches and the company's cash runway into Q2 2028.
- Data from the CARLYSLE trial in SLE (ACR, November 10, 2026) and the ALARIC Phase 1 trial in light-chain amyloidosis (ASH, December 12, 2026).
- CATULUS Phase 2 pediatric r/r B-ALL data by year-end 2027, LUMINA Phase 2 lupus nephritis data in 2028, and BOBCAT Phase 1 progressive MS data in October 2027.
- R&D and SG&A trends as clinical development and commercialization activities continue.
Balance sheet and cash flow
- Cash and cash equivalents: $245,405 thousand at Sep 30, 2026, compared with $104,132 thousand at Dec 31, 2025.
- Marketable securities (available-for-sale debt securities): $2,972 thousand at Sep 30, 2026, compared with $196,578 thousand at Dec 31, 2025.
- Total current assets: $366,784 thousand at Sep 30, 2026, compared with $435,915 thousand at Dec 31, 2025.
- Total assets: $523,059 thousand at Sep 30, 2026, compared with $589,068 thousand at Dec 31, 2025.
- Total current liabilities: $98,647 thousand at Sep 30, 2026, compared with $73,440 thousand at Dec 31, 2025.
- Total liabilities: $495,663 thousand at Sep 30, 2026, compared with $410,939 thousand at Dec 31, 2025.
- Total shareholders' equity: $27,396 thousand at Sep 30, 2026, compared with $178,129 thousand at Dec 31, 2025.
- The company states that the increase in cash, cash equivalents and marketable securities from $201.6 million at June 30, 2026 to $248.4 million at Sep 30, 2026 was primarily driven by net cash inflows from the senior secured note facility from Perceptive Advisors.
- Operating cash flow and free cash flow are not reported in the filing.
Analysis
Autolus reported AUCATZYL net product revenue of $41.2 million for the three months ended September 30, 2026, against $21.1 million a year earlier, an increase of 95% as stated in the release. For the nine months, product revenue was $113,128 thousand against $51,049 thousand. The company attributes the quarter's growth to increasing demand within existing treatment centers and expansion into new centers, supplemented by UK sales. Cost of sales fell to $17.9 million from $28.6 million, and the company reports a gross margin of 57%, up from 55% in the second quarter of 2026 and from a negative gross margin in the year-earlier quarter. Per the company, the year-over-year improvement reflects lower manufacturing cost per batch from higher volumes and efficiency initiatives, as well as lower inventory reserves and write-offs.
Operating spend moved in different directions. Research and development expenses rose to $30.9 million from $27.9 million, which the company links to higher clinical manufacturing supply costs. Selling, general and administrative expenses were $35.9 million against $36.3 million a year earlier. Loss from operations narrowed to $43.5 million from $71.6 million, and net loss narrowed to $55.1 million from $79.1 million. Basic and diluted net loss per ordinary share was $(0.21) against $(0.30). Total other expenses, net increased to $(12,045) thousand from $(6,965) thousand, and the filing does not explain this line in the quarter.
The balance sheet shows a different picture from the income statement. Cash, cash equivalents and marketable securities rose to $248.4 million from $201.6 million at June 30, 2026, which the company attributes primarily to net cash inflows from the Perceptive Advisors senior secured note facility. Total liabilities were $495,663 thousand at September 30, 2026, up from $410,939 thousand at December 31, 2025, and shareholders' equity was $27,396 thousand, down from $178,129 thousand. The company states that current and projected cash, together with AUCATZYL revenues and the combined first and second tranches totaling $100 million from the Perceptive credit facility, will fund operations into Q2 2028.
The company now expects full-year 2026 AUCATZYL net product revenue at or exceeding the upper end of $150 million. The filing does not print an earlier figure for this outlook beyond the phrase "from prior guidance", so the size of the change cannot be measured from the document. No operating cash flow, free cash flow, or capital returns are reported.
On the pipeline, the release moves the first progressive MS data presentation to ECTRIMS Global in October 2027, citing KOL feedback that longer follow-up is needed. Data are expected from CARLYSLE at ACR on November 10, 2026, from ALARIC at ASH on December 12, 2026, from CATULUS by year-end 2027, and from LUMINA in 2028. Investors should weigh the strong revenue and margin trend against the scale of losses, the reduced equity, the dependence on the credit facility tranches for runway, and the safety warnings described in the filing.
Management, verbatim
We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium. Importantly, we also continue to improve the gross margin, with strong execution on manufacturing efficiency initiatives,
Dr. Christian Itin, Chief Executive Officer
AUCATZYL's performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus' proven manufacturing and commercial capabilities.
Dr. Christian Itin, Chief Executive Officer
Not in the filing
stated, not guessed- Prior-year and prior-quarter percentage changes for cost of sales, R&D, SG&A, and loss from operations (not printed as percentages in the filing).
- Numeric prior-year gross margin (the filing says only 'negative' for Q3 2025).
- Prior-year cash, cash equivalents and marketable securities figure for September 30, 2025 (not printed).
- Prior-quarter values for product revenue, operating expenses, loss from operations, and net loss (the filing prints prior-quarter figures only for gross margin and cash).
- Operating cash flow, free cash flow, and capital expenditures.
- Prior guidance figures beyond the phrase 'from prior guidance'; the previous outlook document was not provided.
- Share repurchase and dividend data (none reported).
- Consensus estimates and share price reaction (not in the documents).
- Explanation of the increase in total other expenses, net in the quarter.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Autolus Therapeutics plc (Nasdaq: AUTL) filed a Form 8‑K reporting its third‑quarter 2026 financial results and updated guidance.
Ticker impact
Autolus Therapeutics reported Q3 net product revenue of $41.2M, a 95% YoY increase, and raised full‑year AUCATZYL revenue guidance to the upper end of $150M.
likely upward pressure as investors price in higher revenue and improved margins
Revenue beat and guidance raise indicate stronger demand and margin expansion, which typically lift biotech shares.
Market effects
Boosts outlook for cell‑therapy sector and may lift peer biotech stocks.
Positive for UK‑listed biotech exposure given UK sales contribution.
Highlights growing commercial traction for CAR‑T therapies worldwide.
Counterpoint
If the raised guidance is already priced in, the stock may face a short‑term pull‑back.
Key entities
- companyAutolus Therapeutics plc
Commercial‑stage biopharma developing CAR‑T therapies.
